Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models

Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods. Imatinib mesylate (Gleevec, Novartis Pharma), a tyrosine k...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2014-03, Vol.9 (3), p.e90795
Hauptverfasser:	Gobin, Bérengère, Moriceau, Gatien, Ory, Benjamin, Charrier, Céline, Brion, Régis, Blanchard, Frederic, Redini, Françoise, Heymann, Dominique
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Apoptosis Benzamides - pharmacology Benzamides - therapeutic use Biology Bone cancer Caspases - metabolism Cell Cycle Checkpoints - drug effects Cell death Cell Death - drug effects Cell Line, Tumor Cell Proliferation - drug effects Chemotherapy Disease Models, Animal Disease Progression Dosage and administration Health aspects Humans Imatinib Mesylate Immunocompetence Immunocompetence - drug effects Inhibitor drugs Leukemia Male Medicine Mice Mice, Inbred C57BL Mitosis - drug effects Osteosarcoma Osteosarcoma - drug therapy Osteosarcoma - enzymology Osteosarcoma - pathology Piperazines - pharmacology Piperazines - therapeutic use Preventive medicine Proto-Oncogene Proteins c-akt - metabolism Pyrimidines - pharmacology Pyrimidines - therapeutic use Rats Receptor, Platelet-Derived Growth Factor alpha - metabolism Sarcoma Signal Transduction - drug effects Targeted cancer therapy TOR Serine-Threonine Kinases - metabolism Tumors Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!